马萨诸塞州

我们是谁

  • 7 月 26, 2022
    一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究
  • 7 月 26, 2022
    GCC19CART for Patients With Metastatic Colorectal Cancer
  • 4 月 5, 2022
    CPI-0209 对晚期实体瘤和淋巴瘤患者的研究
  • 4 月 5, 2022
    Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors
  • 4 月 5, 2022
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
  • 4 月 5, 2022
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
  • 4 月 5, 2022
    BMS-986253与Nivolumab或Nivolumab加Ipilimumab联合治疗晚期癌症的研究
  • 4 月 5, 2022
    达拉非尼 + 曲美替尼 + PDR001 在结直肠癌中的应用
  • 4 月 5, 2022
    Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
  • 4 月 5, 2022
    治疗实体瘤患者的 Pembrolizumab 和重组白细胞介素-12